EISAI'S BIOLOGICS DHBL SITE
EXTON, PENNSYLVANIA

Eisai's Exton Campus develops, manufactures and tests biologics targeting cancers or neurodegenerative diseases.

The site is part of our global Deep Human Biology Learning (DHBL) R&D organization.

Exton also supports development of Chemistry, Manufacturing and Controls sections for global regulatory filings and executing technology transfer activities to third-party vendors and partners.

Scientists collaborate with colleagues at Eisai's global discovery centers on biologics development programs throughout their life cycle.

SITE LOCATION

210 Welsh Pool Road
Exton, Pennsylvania 19341, U.S.A.
Telephone: (610) 423-6100

STAFF

Exton currently has a staff of approximately 140, including 110 full-time employees. More than half of the employees have been working at Eisai for over 10 years.

SITE LEADERSHIP

Dr. Joye L. Bramble

Exton Site Head

Vice President
Biopharmaceutical Development of Pharmaceutical Science and Technology

President
Biologics Strategy Unit of the Eisai Demand Chain Systems

COMPOUNDS IN DEVELOPMENT

- Amyloid beta
- Anti-Tau
- EphA4 cleavage
- Ovarian cancer
- Breast cancer

PRIMARY THERAPEUTIC AREAS

Neurology

Oncology

“THE PRIMARY FOCUS OF HEALTH CARE MUST ALWAYS BE THE PATIENT, THE PATIENT’S FAMILY, AND FROM A GENERAL VANTAGEPOINT, THE PUBLIC AS A WHOLE. THESE ARE THE PEOPLE WE MUST SERVE.”

– HARUO NAITO, CEO OF EISAI CO., LTD.

In FY2023, Eisai Exton employees in the U.S. took part in **12 different types of *hhc* activities.** Exton is planning to participate in 22 activities in FY2024.

Eisai’s commitment to the health and well being of people worldwide is embodied in our *human health care (hhc)* mission. To achieve this every employee must spend time with patients and their families to truly understand their perspectives. These insights give us an understanding of their unique experiences, challenges and emotions, which enables us to develop innovative solutions for the prevention, cure and care of disease. **Our *hhc* mission: Putting patients and their families at the heart of everything we do.**

EXTON RESEARCH BUILDING

A wide-variety of biologic therapeutic, research and development within Deep Human Biology Learning (DHBL) is conducted within the 60,000-square-foot Exton Research Building, including antibody generation and engineering, analytical and process development, chemistry, manufacturing and controls (CMC) program management, analytical outsourcing, Development Quality Assurance (DQA), Product Quality (PQ) and site support functions (IT, Facilities, HR, Training).

BIOLOGICS PILOT PLANT

The 60,000-square-foot Biologics Pilot Plant manufactures and tests biologic drug substances, which are created from living organisms, which are used are in preclinical and clinical studies. This LEED certified plant includes 2000L and 1000L bioreactors. It is currently being updated to support the commercialization of novel biological products.

@EisaiUS @Eisai US